IRIS Registry: 11% of patients with wet AMD lost to follow-up

CHICAGO — Factors such as age, race/ethnicity and insurance type increased risk for loss to follow-up in patients with neovascular age-related macular degeneration, according to a study at the American Academy of Ophthalmology meeting.
Rahul N. Khurana, MD, and colleagues sought to determine how many patients on anti-VEGF therapy are lost to follow-up in the United States.
“In order to answer this question, we turned to the largest registry in clinical medicine, the IRIS Registry from the American Academy of Ophthalmology,” he said in a poster presentation. “We looked at

Full Story →